NASDAQ · Pharmaceutical Retailers · USD
High Tide Inc. (HITI) Stock Analysis
High Tide Inc. (HITI) is a Pharmaceutical Retailers stock listed on NASDAQ and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
HITI Key Statistics
As of Sep 4, 2026Trading
- Open
- $2.50
- Previous Close
- $2.52
- Day's Range
- 2.48–2.57
- 52-Week Range
- 2.02–4.06
- Volume
- 404.50K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.08
Valuation
- Market Cap
- $225.39M
- P/E Ratio
- unprofitable
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 15.87
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 0.34
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.40
Financials (FY)
- Revenue (FY)
- $593.99M+13.72%
- Net Income (FY)
- −$50.75M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −6.56%
- Shares Outstanding
- 87.87M
- 1-Year Return
- −19.09%
Dividend and dates
- Earnings Date
- September 14, 2026
- Avg Volume
- 605.34K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
HITI Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −3.21% |
| 2025 | −14.24% |
| 2024 | +89.57% |
| 2023 | +5.84% |
| 2022 | −63.76% |
| 2021 | +34.92% |
As of September 4, 2026.
HITI Revenue and Earnings by Fiscal Year
FY ends October| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $593.99M | −$50.75M | −8.5% |
| 2024 | $522.31M | −$4.34M | −0.8% |
| 2023 | $487.67M | −$39.31M | −8.1% |
| 2022 | $356.85M | −$71.76M | −20.1% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $593.99M | $153.53M | $15.44M | −$50.75M | −8.5% |
| 2024 | $522.31M | $142.50M | $15.32M | −$4.34M | −0.8% |
| 2023 | $487.67M | $131.31M | −$2.66M | −$39.31M | −8.1% |
| 2022 | $356.85M | $100.95M | −$20.11M | −$71.76M | −20.1% |
Annual figures as reported, in the company's reporting currency. As of October 31, 2025.
HITI Valuation vs Pharmaceutical Retailers Median
Median of 6 stocks| Metric | HITI | Pharmaceutical Retailers median | vs median |
|---|---|---|---|
| P/S ratio | 0.34 | 0.34 | 0% above |
| Profit margin | −6.56% | −11.95% | 5.4 pts above |
Medians across 6 Pharmaceutical Retailers stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
High Tide: German Expansion Just Added Another Bullish Catalyst
SeekingAlphaHigh Tide Sees Prelim Q3 Sales $195.000M-$200.000M vs $171.167M Est
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Pharmaceutical Retailers Stocks
TelyRx Holdings Inc.
$65.15M
PETSPetMed Express, Inc.
$39.24M
SCNXScienture Holdings, Inc.
$15.32M
RDGTRidgetech, Inc.
$3.30M
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B

